Success Metrics

Clinical Success Rate
82.0%

Based on 123 completed trials

Completion Rate
82%(123/150)
Active Trials
29(13%)
Results Posted
63%(77 trials)
Terminated
27(12%)

Phase Distribution

Ph not_applicable
15
7%
Ph phase_4
17
8%
Ph phase_1
59
27%
Ph early_phase_1
4
2%
Ph phase_2
102
46%
Ph phase_3
20
9%

Phase Distribution

63

Early Stage

102

Mid Stage

37

Late Stage

Phase Distribution217 total trials
Early Phase 1First-in-human
4(1.8%)
Phase 1Safety & dosage
59(27.2%)
Phase 2Efficacy & side effects
102(47.0%)
Phase 3Large-scale testing
20(9.2%)
Phase 4Post-market surveillance
17(7.8%)
N/ANon-phased studies
15(6.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.4%

123 of 161 finished

Non-Completion Rate

23.6%

38 ended early

Currently Active

29

trials recruiting

Total Trials

220

all time

Status Distribution
Active(34)
Completed(123)
Terminated(38)
Other(25)

Detailed Status

Completed123
Terminated27
unknown25
Recruiting21
Withdrawn11
Active, not recruiting8

Development Timeline

Analytics

Development Status

Total Trials
220
Active
29
Success Rate
82.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (1.8%)
Phase 159 (27.2%)
Phase 2102 (47.0%)
Phase 320 (9.2%)
Phase 417 (7.8%)
N/A15 (6.9%)

Trials by Status

not_yet_recruiting52%
completed12356%
recruiting2110%
unknown2511%
withdrawn115%
terminated2712%
active_not_recruiting84%

Recent Activity

Clinical Trials (220)

Showing 20 of 220 trialsScroll for more
NCT00001529

Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Recruiting
NCT07602777Phase 1

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

Recruiting
NCT01511562Phase 2

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Completed
NCT03182244Phase 3

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Completed
NCT01857934Phase 2

Therapy for Children With Advanced Stage Neuroblastoma

Completed
NCT02782546Phase 2

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Active Not Recruiting
NCT02436707Phase 2

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active Not Recruiting
NCT04558736Phase 2

Haploidentical HCT for Severe Aplastic Anemia

Recruiting
NCT03849651Phase 2

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active Not Recruiting
NCT06207799Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Recruiting
NCT03480360Phase 3

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Completed
NCT07637851Phase 1

Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

Not Yet Recruiting
NCT02231879Phase 2

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

Completed
NCT02375204Phase 3

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Active Not Recruiting
NCT07002827Not Applicable

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Recruiting
NCT06528691Phase 2

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Recruiting
NCT07428486Phase 1

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Withdrawn
NCT04872595Phase 2

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

Active Not Recruiting
NCT01163942Phase 3

Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)

Terminated
NCT03164057Phase 2

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
220